We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+40.85%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$468M
AUM Growth
+$110M
Cap. Flow
-$14.6M
Cap. Flow %
-3.12%
Top 10 Hldgs %
97.64%
Holding
17
New
1
Increased
1
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
NCNA
NuCana
NCNA
+$18.1M
2
VRNA
Verona Pharma
VRNA
+$10.7M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$23M
2
PSNL icon
Personalis
PSNL
+$19.6M
3
TARA icon
Protara Therapeutics
TARA
+$765K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$8.01B
$206M 44.03%
4,168,718
– –
PSNL icon
2
Personalis
PSNL
$1.4B
$96.7M 20.68%
4,462,452
-986,842
-18% -$19.6M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$849M
$44.5M 9.52%
1,203,135
– –
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
$25.8M 5.51%
686,840
– –
CRSP icon
5
CRISPR Therapeutics
CRSP
$4.63B
$21.7M 4.64%
259,599
-259,599
-50% -$23M
NCNA
6
NuCana
NCNA
$5.45M
$17.2M 3.69%
+667
New +$18.1M
VRNA
7
DELISTED
Verona Pharma
VRNA
$15.3M 3.28%
2,457,499
+1,555,556
+172% +$10.7M
XCUR icon
8
Exicure
XCUR
$12M
$12.1M 2.58%
46,513
– –
SRRA
9
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$9.21M 1.97%
876,541
– –
SIEN
10
DELISTED
Sientra, Inc.
SIEN
$8.13M 1.74%
239,084
– –
PRTK
11
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.62M 1.2%
1,041,131
– –
MTEM
12
DELISTED
Molecular Templates, Inc.
MTEM
$2.18M 0.47%
13,333
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$8.45B
$1.7M 0.36%
9,620
– –
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$947K 0.2%
131,036
– –
TARA icon
15
Protara Therapeutics
TARA
$229M
$344K 0.07%
20,610
-33,002
-62% -$765K
OBSV
16
DELISTED
ObsEva SA Ordinary Shares
OBSV
$218K 0.05%
87,999
– –
OCGN icon
17
Ocugen
OCGN
$450M
$2K ﹤0.01%
7,111
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2020 Portfolio in Review

As of Q3 2020, Abingworth held 17 positions worth $468M, up 31% from $358M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Abingworth withdrew a net $14.6M in Q3 2020, reducing 3 holdings. Its largest reduction was CRISPR Therapeutics, cutting an estimated $23M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Abingworth opened a new position in NuCana worth $17.2M.

  • Abingworth's largest Q3 2020 buy was NuCana: 667 shares worth $17.2M.
  • Abingworth added most to Verona Pharma in Q3 2020, an estimated $10.7M increase.
  • Abingworth's biggest Q3 2020 reduction was CRISPR Therapeutics, cutting an estimated $23M.
  • Abingworth's ten largest holdings make up 98% of its $468M portfolio in Q3 2020.
  • Abingworth opened 1 new position and closed 0 in Q3 2020.
  • Abingworth's portfolio value rose 31% quarter-over-quarter to $468M.

Based on Abingworth's 13F filing for Q3 2020, filed 16 Nov 2020.